What captured your attention on DRUGDOCS® in July?
1️⃣ Yeztugo® for chronic myeloid leukemia
2️⃣ Yorvipath® to slash LDL-C via PCSK9 inhibition
3️⃣ Lynozyfic® GLP-1 agonist for type 2 diabetes

🔍 All the data, all the studies, right here: drugdocs.com
#Yeztugo #Yorvipath #Lynozyfic

YORVIPATH Becomes First Approved Treatment for Chronic Hypoparathyroidism in Australia The Therapeutic Goods Administration in Australia has approved YORVIPATH, a pioneering treatment for chronic hypoparathyroidism, offering hope to many patients.

YORVIPATH Becomes First Approved Treatment for Chronic Hypoparathyroidism in Australia #Australia #Melbourne #YORVIPATH #Chronic_Hypoparathyroidism #Specialised_Therapeutics

#yorvipath #hypoparathyroidism

Orsini Partners with Ascendis to Distribute YORVIPATH® for Rare Disorder Treatment Orsini has been appointed by Ascendis Pharma as the specialty pharmacy partner for YORVIPATH®, a treatment for hypoparathyroidism in adults, highlighting their commitment to rare diseases.

Orsini Partners with Ascendis to Distribute YORVIPATH® for Rare Disorder Treatment #United_States #Elk_Grove_Village #Ascendis_Pharma #YORVIPATH #Orsini